584 related articles for article (PubMed ID: 28924629)
21. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
[TBL] [Abstract][Full Text] [Related]
22. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
[TBL] [Abstract][Full Text] [Related]
23. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
24. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
27. Preparation of
Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
29.
Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
[TBL] [Abstract][Full Text] [Related]
30. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
31. Hetero-bivalent agents targeting FAP and PSMA.
Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291
[TBL] [Abstract][Full Text] [Related]
32. Radiochemistry and In Vivo Imaging of [
Saini S; Mullen GED; Blower PJ; Lapi SE
Mol Pharm; 2024 Feb; 21(2):822-830. PubMed ID: 38173242
[TBL] [Abstract][Full Text] [Related]
33. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
34. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
35. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
[TBL] [Abstract][Full Text] [Related]
36. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.
Banerjee SR; Pullambhatla M; Byun Y; Nimmagadda S; Green G; Fox JJ; Horti A; Mease RC; Pomper MG
J Med Chem; 2010 Jul; 53(14):5333-41. PubMed ID: 20568777
[TBL] [Abstract][Full Text] [Related]
37. Repeatability of [
Osborne JR; Kalidindi TM; Punzalan BJ; Gangangari K; Spratt DE; Weber WA; Larson SM; Pillarsetty NVK
Mol Imaging Biol; 2017 Dec; 19(6):944-951. PubMed ID: 28534214
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo comparative study of a novel
Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
[No Abstract] [Full Text] [Related]
39. A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen.
Hao G; Kumar A; Dobin T; Oz OK; Hsieh JT; Sun X
Mol Pharm; 2013 Aug; 10(8):2975-85. PubMed ID: 23768233
[TBL] [Abstract][Full Text] [Related]
40. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
